CAR T-cell Therapy Market Size, Share & Industry Analysis, By Product (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, and Others), By Indication (Large B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, B-cell Acute Lymphoblastic Leukemia, Multiple Myeloma, and Others), By Age Group (Pediatric and Adults), By End User (Hospital-based CAR T-cell Treatment Centers, Standalone Cancer Treatment Centers, and Others), and Regional Forecast, 2026-2034

Last Updated: September 16, 2026 | Format: PDF | Report ID: FBI108455

Buy Now

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 7.34% from 2026-2034
Unit	Value (USD billion)
Segmentation	By Drug Type Axicabtagene Ciloleucel (Yescarta) Brexucabtagene Autoleucel (Tecartus) Ciltacabtagene Autoleucel (Carvykti) Idecabtagene Vicleucel (Abecma) Lisocabtagene Maraleucel (Breyanzi) Tisagenlecleucel (Kymriah) Others
	By Indication Acute Lymphoblastic Leukemia Non-Hodgkin Lymphoma Multiple Myeloma
	By End-user Hospitals Oncology Treatment Centers
	By Region North America (By Drug Type, By Indication, By End-user, By Country) U.S. Canada Europe (By Drug Type, By Indication, By End-user, By Country/Sub-region) Germany U.K. France Italy Spain Scandinavia Rest of Europe Asia Pacific (By Drug Type, By Indication, By End-user, By Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Rest of the World (By Drug Type, By Indication, By End-user)